By: IPP Bureau
Last updated : November 06, 2025 12:48 pm
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
EazeBio announced a strategic partnership with the University of California, Santa Cruz (UC Santa Cruz) to advance and commercialize a groundbreaking instrument-free diagnostic platform.
The collaboration will co-develop an innovative cortisol biosensor for stress and metabolic health testing, combining EazeBio’s expertise in affordable, scalable biotechnology with UC Santa Cruz’s deep research capabilities.
Together, they aim to accelerate the development of next-generation, lab-independent testing for global health applications.
“At EazeBio, we are committed to transforming the way diagnostics reach people,” said Reem Mahrat, CEO and Founder of EazeBio. “Our partnership with UC Santa Cruz brings together world-class science and mission-driven innovation to create a platform built not just for performance—but for global health equity. This latest technology brings the lab to the patient, not the other way around.”
Rooted in UC Santa Cruz’s cutting-edge biosensing research and inspired by Nobel Prize-winning science, the platform represents a significant leap forward in point-of-care diagnostics—combining innovative detection chemistry with luminescent biosensors, modular assay design, and AI-guided interpretation. It’s engineered for speed, affordability, and accessibility—requiring no instrumentation, refrigeration, or specialized training. The result: lab-quality performance without the need for traditional laboratory infrastructure.
With a shared commitment to equitable healthcare access and scientific excellence, the collaboration between UC Santa Cruz and EazeBio is poised to shape the next frontier in decentralized diagnostics.
“My group is developing lab prototypes with real translational potential, and it’s deeply rewarding to hear from patients who need these sensors to improve their health,” said Andy Yeh, assistant professor of biomolecular engineering at the UC Santa Cruz Baskin School of Engineering. “AI-based protein design now lets us tackle questions once thought impossible, and I’m excited to see EazeBio translating this technology and driving progress toward making a meaningful difference in people's lives.”
Dr. Belal Abdallah, MD, MBA, CPE and Clinical Advisor at EazeBio, added, “As a clinician and CEO of an accountable care organization, I've seen firsthand how diagnostic delays exacerbate health disparities. EazeBio's instrument-free platform, born from this groundbreaking UC Santa Cruz collaboration, flips the script—bringing precision medicine to the patient's doorstep with speed, affordability, and equity. This isn't just a tool; it's a catalyst for reimagining accountable care in the 21st century.”